Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: REGN.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Regeneron Pharmaceuticals (REGN) Stock Forecast and AI Rating

Deep analysis published Sep 20 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

$883

+12.4%+12.9% incl. dividends

2031

5-Year

BUY

$1,302

+65.9%+69.2% incl. dividends

Published batch insight

Unencumbered Cash Royalty Inflection Overpowers Terminal Biopharma Patent Cliff Fears

High consensus confirms that unencumbered partner royalties and high-dose formulation defense offset legacy biosimilar erosion, driving structural free cash flow expansion. While sharp divergence exists regarding outer-year terminal multiple compression ahead of 2031 patent expirations, pristine net cash provides defensive insulation.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath), Warren Buffett (Value Purist), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower), Superintelligence (Anthropologist), Ray Dalio (Strategist), Elon Musk (Visionary), Machiavelli (Insider), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Regeneron Pharmaceuticals at publication: $16,920 in five years versus $13,892 for S&P 500 benchmark.

Regeneron Pharmaceuticals · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 0.4% net dividend yield for Regeneron Pharmaceuticals.

Figure: Five-year synthesized consensus value path for Regeneron Pharmaceuticals compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 784.85 USD1-year price return: +12.45%5-year price return: +65.86%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter / date	Target (USD)	Quarter return	Total return	Forecast rationale
Q118 Dec 2026	815.86	+3.95%	+3.95%	Reported results confirm the initial profit uplift following full satisfaction of partner development liabilities. Expanding immunology royalties and steady high-dose ocular conversion absorb broader equity market rate volatility, driving moderate valuation stabilization.
Q218 Mar 2027	819.38	+0.43%	+4.40%	Initial standard-dose biosimilar entries introduce wholesale pricing concessions, producing tactical margin friction. However, high-dose volume retention and uninterrupted partner cash flows limit downside, maintaining orderly per-share fundamental consolidation.
Q318 Jun 2027	853.60	+4.18%	+8.76%	Unencumbered collaboration cash flows expand reported operating margins by several hundred basis points. Sustained global respiratory volume growth accelerates cash generation, driving consensus upward revisions across institutional equity research desks.
Q418 Sept 2027	882.56	+3.39%	+12.45%	High-dose formulation captures over sixty percent of franchise volume, blunting competitive generic headlines. Accelerated share repurchases funded by substantial liquid reserves steadily absorb floating equity supply, bolstering per-share intrinsic value.
Q518 Dec 2027	914.14	+3.58%	+16.47%	Late-stage pipeline progression across oncology and metabolic indications improves terminal visibility. Year-end portfolio rebalancing favors cash-generative biopharmaceutical assets with zero net leverage, supporting steady multiple resilience against macro rate persistence.
Q618 Mar 2028	924.80	+1.17%	+17.83%	Annual financial reporting showcases record operational cash flow exceeding four billion dollars. Statutory federal pricing disclosures create transient headline drag, but superior balance-sheet strength and ex-U.S. expansion cushion operating profitability.
Q718 Jun 2028	960.98	+3.91%	+22.44%	Pivotal clinical trial readouts for adjunctive metabolic therapies demonstrate functional lean-mass preservation, sparking institutional interest. Concurrently, unencumbered partnership income reaches new records, sustaining robust top-line momentum across core disease areas.
Q818 Sept 2028	990.47	+3.07%	+26.20%	Commercial execution proves high-dose retinal regimens effectively lock in specialist loyalty despite multi-competitor generic availability. Systematic treasury buybacks continue shrinking diluted share count, compounding fundamental earnings per share growth.
Q918 Dec 2028	1,026.10	+3.60%	+30.74%	Global immunology sales maintain strong double-digit expansion, dropping significant cash directly to the bottom line. Corporate leadership expands capital return authorizations, closing the year with solid operational performance and pristine liquidity.
Q1018 Mar 2029	1,053.77	+2.70%	+34.26%	Full-year results confirm operating margins stabilizing near peak levels. However, analysts begin publishing long-term exclusivity transition scenarios, causing modest multiple restraint even as underlying business net earnings advance.
Q1118 Jun 2029	1,079.91	+2.48%	+37.59%	Initial two-year forward discounting of key biologic patent expiries introduces valuation friction. Pipeline diversification into bispecific oncology and rare diseases accelerates, partially counterbalancing market-wide duration trimming among institutional investors.
Q1218 Sept 2029	1,108.81	+2.68%	+41.28%	Accretive share repurchases executed at discounted forward multiples mechanically support equity value. Commercial revenues from wholly owned oncology products expand, proving internal research efficiency replaces aging revenue pillars without dilutive acquisitions.
Q1318 Dec 2029	1,138.92	+2.72%	+45.11%	Expanded international penetration across emerging territories offsets domestic reimbursement concessions. High cash conversion sustains significant internal laboratory reinvestment while preserving an unassailable net-cash fortress against broader macroeconomic instability.
Q1418 Mar 2030	1,153.66	+1.29%	+46.99%	Full-year filings show cumulative five-year share shrinkage approaching fifteen percent, magnifying per-share metrics. Nevertheless, closer proximity to prime compound patent dates caps price-to-earnings expansion, keeping capital appreciation disciplined.
Q1518 Jun 2030	1,186.35	+2.83%	+51.16%	Commercial rollout of adjacent metabolic therapies and next-generation bispecifics begins generating meaningful revenue streams. Operational scale and high gross margins ensure cash flow remains resilient through shifting competitive dynamics.
Q1618 Sept 2030	1,201.12	+1.25%	+53.04%	Generalist institutional capital selectively de-risks ahead of terminal patent milestones, inducing modest multiple compression. Defensive pharmaceutical demand and zero refinancing vulnerability limit downside volatility relative to broader healthcare equities.
Q1718 Dec 2030	1,233.15	+2.67%	+57.12%	Final pre-cliff financial disclosures deliver record free cash flow, attracting value-focused institutional buyers. Treasury execution aggressively retires shares, establishing firm valuation support and closing the year on sound operational delivery.
Q1818 Mar 2031	1,244.03	+0.88%	+58.51%	Primary composition-of-matter exclusivity expiration generates elevated media scrutiny and short-term multiple de-rating. Underlying operations remain robust as secondary formulation protections, complex manufacturing, and patient stickiness prevent immediate revenue collapse.
Q1918 Jun 2031	1,276.23	+2.59%	+62.61%	Observed commercial erosion proves substantially more gradual than pessimistic models projected, supported by durable international contracts and device patents. A relief repricing unfolds as first-half cash realization exceeds cautious trough expectations.
Q2018 Sept 2031	1,301.75	+2.00%	+65.86%	The five-year transformation culminates with an unencumbered, multi-pillar commercial structure. Substantially reduced share count, newly scaled oncology and metabolic franchises, and pristine liquidity establish an enduring, high-return biopharmaceutical compounder.

The central economic argument resolves the conflict between imminent patent expirations and structural cash-flow acceleration. While legacy standard-dose aflibercept faces multi-competitor biosimilar erosion, rapid commercial migration to the high-dose formulation effectively insulates retinal cash flows through extended dosing durability. Concurrently, the mid-2026 satisfaction of the partner development balance permanently eliminates historical collaboration profit withholdings, releasing an unencumbered cash waterfall from expanding global immunology indications. Trading near nineteen times trailing earnings, the asset heavily discounts this margin step-up. Valuation sensitivity centers on terminal multiple compression: as the March 2031 compound patent expiration approaches, multiple contraction will partially offset substantial non-GAAP earnings compounding. The primary counterargument warns that aggressive payer step-therapy mandates could accelerate retinal pricing deflation while heavy expensed research outlays drag intermediate operating leverage.

Key insights

Unencumbered collaboration profit splits structurally elevate operating cash generation, converting expanding global respiratory volumes into high-margin net income without incremental capital expenditure.
High-dose formulation switching dynamics create steep physician switching barriers, neutralizing first-wave generic biosimilar encroachment and extending ophthalmic cash-flow duration.
Pristine net liquidity exceeding fifteen billion dollars facilitates continuous anti-dilutive equity cannibalization, mechanically amplifying per-share intrinsic value through cyclical macroeconomic fluctuations.

Deep Dive

Prevailing market sentiment treats the business as an ex-growth asset trapped behind an insurmountable patent cliff. Consensus fixates on incoming aflibercept biosimilars and legislative drug price negotiations, assuming eye-care revenue will collapse. Sell-side models anchor heavily on legacy product margin compression, lazily projecting terminal decay while overlooking the cash inflection created by the extinguished partnership development debt and accelerating respiratory therapy expansion.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates value by mistaking a managed lifecycle transition for structural obsolescence. Market participants commit an analytical error by valuing the equity against historical financials that included substantial partner development withholdings, which fully terminated in mid-2026. Furthermore, consensus fails to recognize that high-dose conversions preserve specialized eye revenues, while nearly six billion dollars in expensed annual scientific discovery conceals true economic earning power. This creates a compelling underpricing gap relative to durable recurring cash flows.

Repricing catalyst

Consecutive quarterly financial reports through 2027 will expose the market's mispricing as unencumbered partnership profits visibly expand reported operating margins. Tangible evidence will emerge as high-dose retinal market share surpasses sixty percent while immunology revenue outpaces legacy price erosion. This operational delivery will force sell-side analysts to execute upward earnings-per-share revisions and dismantle terminal-decline valuation assumptions.

Published consensus context

Macro regime alignment

The prevailing restrictive monetary policy regime of four percent benchmark interest rates acts as a relative tailwind for this asset. Operating with negative net debt and over fifteen billion dollars in liquid reserves, the company generates significant interest income while leveraged biotech competitors suffer. Inelastic demand for sight-saving and chronic inflammatory treatments provides robust pricing insulation against broader macroeconomic volatility.

Published consensus context

Advisor disagreement

The decisive debate centers on valuation horizon and terminal exclusivity dynamics rather than near-term operational health. Bullish reports model sustained multiple expansion past twenty-two times forward earnings, assuming proprietary metabolic and oncology pipelines will seamlessly offset maturing blockbusters. Conversely, more skeptical assessments point to historical precedent, arguing that large-cap biopharma multiples inevitably compress into the low-to-mid teens as primary compound patents near expiration, irrespective of pipeline potential. Resolving this conflict requires monitoring whether high-dose retinal formulations maintain volume above sixty percent against 2027 biosimilars and whether Phase 3 metabolic data demonstrate reimbursable functional endpoints.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Unencumbered immunology collaboration profit unlock: Full satisfaction of the historical partner development balance in mid-2026 permanently eliminates collaboration profit withholdings. This structural reset allows the complete fifty-percent commercial profit split to drop directly to operating income. Supported by blockbuster expansion into chronic obstructive pulmonary disease, high-margin royalty streams expand significantly across the forecast horizon. Expected impact: +27%.
High-dose formulation ophthalmic franchise defense: Rapid clinical adoption of the high-dose eight-milligram formulation preserves ophthalmic franchise cash generation against incoming standard-dose biosimilars. Extended dosing intervals up to sixteen and twenty weeks erect formidable prescriber switching frictions. High-dose conversion protects net realized pricing, cushioning the business against legacy volume loss through dense secondary patent estates. Expected impact: +18%.
Disciplined anti-dilutive share retirement compounding: Management consistently channels substantial free cash flow into open-market share repurchases, retiring approximately three to four percent of outstanding equity annually. Backed by pristine net liquidity and zero debt-refinancing exposure, continuous float reduction mechanically accelerates per-share earnings growth, establishing a durable fundamental floor beneath quoted equity valuations. Expected impact: +15%.
Proprietary genetic platform discovery productivity: The integrated genetic discovery engine and antibody validation technologies consistently deliver proprietary clinical candidates at a fraction of external licensing costs. Generating validated oncology bispecifics and rare disease assets in-house preserves high returns on capital, systematically replacing maturing commercial therapies with wholly owned, patent-protected biological monopolies. Expected impact: +16%.

Top frictions and headwinds

Standard-dose aflibercept biosimilar pricing compression: Multiple settled biosimilar entries beginning late 2026 force steep price discounting on legacy two-milligram vials. Payer step-edits and commercial formulary tiering mandate cheaper alternatives, eroding baseline ophthalmic net realization. While high-dose migration mitigates volume loss, the aggregate retinal revenue pool faces inevitable margin drag over the medium term. Expected impact: -18%.
March 2031 compound patent cliff discounting: The primary United States composition-of-matter patent for the flagship immunology biologic expires in March 2031. Because institutional equity markets discount biologic loss of exclusivity two to three years in advance, valuation multiple compression will increasingly penalize forward earnings from 2029 onward despite expanding underlying operational revenue. Expected impact: -15%.
High expensed scientific research intensity: Management maintains an aggressive discovery commitment, pouring nearly six billion dollars annually into internal research and development at over thirty-five percent of revenues. Fully expensing late-stage clinical programs directly against current income depresses reported accounting margins, constraining near-term operating leverage during macroeconomic tightening cycles. Expected impact: -10%.
Federal drug price negotiation frameworks: Statutory drug price negotiation mandates under federal healthcare legislation enforce mandatory ceiling discounts and rebate penalties on mature biologic blockbusters. Increasing public-payer scrutiny across Medicare Part B and Part D channels threatens net realized pricing, dampening the long-term earnings potential of high-expenditure chronic commercial therapies. Expected impact: -10%.

Tail risks

Judicial invalidation of high-dose formulation patents: An unexpected federal appellate ruling overturning preliminary injunctions and invalidating secondary patents protecting high-dose aflibercept would allow immediate generic eight-milligram market entry. Dismantling the retinal lifecycle defense would trigger violent thirty-to-fifty percent price deflation, slashing domestic ophthalmology cash generation by over a billion dollars annually. Probability: +27%. Expected impact: -28%.
Binary Phase 3 pipeline failure shock: Severe safety alerts or statistical failure in pivotal late-stage cardiometabolic or bispecific oncology trials would eliminate critical pipeline diversification options. Mirroring past single-day trial setbacks, stranded developmental capital and the loss of post-2031 replacement revenue would trigger an abrupt de-rating toward low-teens terminal multiples. Probability: +23%. Expected impact: -24%.

Tail opportunities

Cardiometabolic obesity muscle preservation breakthrough: Pivotal Phase 3 clinical data validating trevogrumab in combination with incretin agonists could establish a dominant therapeutic standard for preserving lean muscle mass during weight loss. Proving functional body composition benefits would unlock a massive multi-billion-dollar adjunctive metabolic market by 2028, sparking aggressive multiple expansion. Probability: +34%. Expected impact: +36%.
Immunology primary patent exclusivity extension: Favorable patent term extensions and federal court validation of secondary formulation and method-of-treatment claims could stretch core immunology exclusivity past 2033. Disclosed legal victories would eliminate the looming terminal valuation overhang, prompting immediate double-digit structural repricing across institutional discounted cash flow models. Probability: +32%. Expected impact: +25%.

What to monitor

Thesis watchpoints

Consensus monitoring prioritizes three decisive operational checkpoints:

Key insights

High-dose retinal formulation maintaining over sixty percent combined franchise volume through late 2027 confirms successful generic defense.
Quarterly unencumbered collaboration revenue decelerating below twelve percent year-over-year growth signals saturation or severe payer formulary pushback.
Phase 3 metabolic trials failing primary lean-mass preservation endpoints or adverse high-dose patent rulings mandate immediate valuation reassessment.

Company Financial Analysis

Regeneron Pharmaceuticals Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

The company's headline financial results show an accelerating top line, with second-quarter 2026 revenue expanding 17% year-over-year to $4.29 billion. Although accounting net income dipped slightly due to clinical trial spending and one-off research charges, cash flow tells a much stronger story. Blockbuster immunology sales surged 38% globally to $6.0 billion, demonstrating that demand is expanding rather than slowing. Crucially, the full repayment of a $3.1 billion partnership development balance in mid-2026 fundamentally changes the earnings picture. Operating free cash flow of $3.52 billion easily funds heavy research reinvestment. Removing historical partnership profit deductions allows commercial gains to flow directly into company earnings, establishing a higher, unencumbered baseline for future profits.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 14.3B	USD 4.5B	USD 4.1B
2024	USD 14.2B	USD 4.4B	USD 3.7B
2023	USD 13.1B	USD 4B	USD 3.7B
2022	USD 12.2B	USD 4.3B	USD 4.4B
2021	USD 16.1B	USD 8.1B	USD 6.5B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	18.4x	TTM	Native	USD / USD
2024	18.4x	TTM	Native	USD / USD
2023	25.3x	TTM	Native	USD / USD
2022	19.0x	Annual	Native	USD / USD
2021	8.9x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Gross profit margins remain world-class at 85.4%, demonstrating formidable pricing power and highly efficient manufacturing across complex biologic therapies. Operating margins moderated toward 25% from pandemic peaks, driven entirely by deliberate increases in research spending and promotional costs for new product launches rather than structural operational decay. Profit margins are now positioned for a structural rebound. Eliminating the partnership development reimbursement liability removes a multi-hundred-million-dollar quarterly profit drag. As high-margin partnership royalties flow unhindered and upgraded high-dose formulations achieve manufacturing scale, operating margins should naturally expand back toward 30% over the coming years.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 3.6B	24.9%	31.4%
2024	USD 4B	28.1%	31.1%
2023	USD 4B	30.9%	30.1%
2022	USD 5.4B	44.2%	35.6%
2021	USD 8.9B	55.7%	50.2%

Balance sheet and leverage

AI Review

The balance sheet functions as an impregnable financial fortress, holding over $17.8 billion in cash and marketable securities against minimal gross debt. With a debt-to-equity ratio of just 0.09 and an interest coverage ratio exceeding 120 times, the company faces virtually zero financial solvency risk in a high-interest-rate environment. This pristine liquidity structure provides total strategic autonomy. Unburdened by debt covenants or refinancing pressures, management deployed nearly $4.0 billion into share buybacks in 2025. This exceptional financial strength allows the business to fund late-stage clinical programs independently while taking advantage of market dips to retire undervalued shares.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 2.7B	USD 8.6B	USD 412.2M net cash	4.13x
2024	USD 2.7B	USD 9B	USD 216.2M net debt	4.73x
2023	USD 2.7B	USD 10.8B	USD 27.1M net cash	5.69x
2022	USD 2.7B	USD 7.7B	USD 404.5M net cash	5.06x
2021	USD 2.7B	USD 5.7B	USD 185.9M net cash	3.56x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management's capital strategy focuses heavily on internal scientific discovery rather than buying expensive external businesses. Physical spending on buildings and manufacturing remained modest at roughly 6.3% of revenue in 2025, directed toward state-of-the-art biologic facilities. In contrast, expensed research and development absorbed $5.85 billion, representing nearly 40% of sales. This massive research commitment depresses short-term reported accounting profits, but it builds valuable long-term biological assets. By inventing medicines in-house through proprietary genetic platforms, the company avoids dilutive acquisitions and creates high returns on capital. This internal development pipeline ensures a steady stream of next-generation therapies to replace older mature products.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 898.4M	USD 5.9B
2024	USD 755.9M	USD 5.2B
2023	USD 926.4M	USD 4.4B
2022	USD 590.1M	USD 3.1B
2021	USD 551.9M	USD 2.6B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	209	+13%	Not available	ORIGINAL
5Y	BUY	184	+73.4%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	800.55	814.56	847.64	14
+6M	March 18, 2027	776.53	821.46	848.89	14
+9M	June 18, 2027	815.36	854.83	882.85	14
+1Y	September 18, 2027	832.64	883.54	917.56	14
+15M	December 18, 2027	865.95	914.36	950.8	14
+18M	March 18, 2028	854.91	930.61	974.08	14
+21M	June 18, 2028	897.66	965.08	1,022.78	14
+2Y	September 18, 2028	918.86	994.72	1,053.47	14
+27M	December 18, 2028	955.62	1,031.02	1,094.59	14
+30M	March 18, 2029	974.73	1,060.62	1,136.16	14
+33M	June 18, 2029	951.38	1,090.64	1,184.9	14
+3Y	September 18, 2029	979.92	1,121.39	1,232.29	14
+39M	December 18, 2029	999.52	1,150.18	1,269.26	14
+42M	March 18, 2030	959.54	1,173.32	1,320.03	14
+45M	June 18, 2030	978.73	1,207.9	1,372.83	14
+4Y	September 18, 2030	949.37	1,226.99	1,414.02	14
+51M	December 18, 2030	968.36	1,259.57	1,442.3	14
+54M	March 18, 2031	919.94	1,275.85	1,485.57	14
+57M	June 18, 2031	947.54	1,308.65	1,515.28	14
+5Y	September 18, 2031	966.49	1,335.03	1,545.59	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The independently supported consensus reveals an enterprise executing an effective commercial transition: full repayment of the multi-billion-dollar partner development balance in mid-2026 unlocks unencumbered immunology profit splits, while high-dose retinal adoption insulates core ophthalmic volume against standard biosimilars. However, correlated assumptions across several reports treat pipeline options as guaranteed commercial blockbusters and underestimate outer-year multiple compression ahead of the March 2031 primary compound expiration. The strongest contrarian perspective demonstrates that even with robust near-term earnings growth, valuation multiples naturally compress as terminal patent expiries enter standard institutional discounting windows. Material limitations include unresolved regulatory price-setting under federal frameworks and clinical translation uncertainty in adjacent metabolic combinations. Consequently, weight is concentrated in reports demonstrating rigorous primary-source grounding, audited collaboration mechanics, and disciplined terminal multiple restraint.

AI RESEARCHER

11.76%Weight

Universal Investor AI

The Polymath

Opus 5

Exceptional primary-source grounding across filings, patent settlements, and clinical trial results anchors a realistic terminal discounting framework. By properly modeling the 2029-2031 multiple compression ahead of compound patent expiration, it delivers superior causal consistency.

AI RESEARCHER

9.80%Weight

Universal Investor AI

The Polymath

GPT-6 Astra

Exceptional primary financial verification accurately separates operating cash flow from non-operating distortions. Its balanced bridge models post-repayment margin uplift alongside persistent R&D intensity, providing an objective, highly disciplined valuation foundation.

AI RESEARCHER

8.82%Weight

Universal Investor AI

The Polymath

Gemini 3.8 Flash

This analysis provides excellent empirical detail on quarterly collaboration receipts, reimbursement dynamics, and cash conversion cycles. Its conservative trajectory accounts for patent cliff headwinds while crediting unencumbered cash flows, justifying high relative conviction.

AI THINKER

7.84%Weight

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Strong forensic accounting links top-line expansion to unencumbered collaboration receipts while maintaining realistic expectations for clinical pipeline progress. It provides balanced treatment of operating reinvestment, earning an above-average weight.

AI RESEARCHER

7.84%Weight

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Comprehensive verification of patent settlement dates and high-dose conversion benchmarks provides high evidential rigor. Its realistic compounding path connects robust cash generation with continuous share buybacks, supporting a solid allocation.

AI RESEARCHER

7.84%Weight

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Rigorous macroeconomic positioning highlights the fortress balance sheet's resilience amid restrictive interest rates. Its debt-free compounding thesis is causal and robust, though outer-year multiple expansion assumptions are moderately generous.

AI RESEARCHER

6.86%Weight

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

The thesis provides solid mechanistic clarity regarding the Sanofi development debt payoff and high-dose formulation switching dynamics. However, its earnings trajectory slightly understates regulatory drug price negotiation friction, justifying a measured weighting.

AI RESEARCHER

6.86%Weight

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

The perspective offers sharp tactical insight into reimbursement contracts and executive pricing strategy. While its political durability assumptions are somewhat optimistic, its evaluation of payer step-therapy risks is highly grounded and actionable.

AI RESEARCHER

6.86%Weight

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Forensic balance sheet verification confirms the full satisfaction of off-balance-sheet collaboration liabilities. The thesis accurately isolates the operating margin inflection while maintaining prudent skepticism regarding recent oncology pipeline setbacks.

AI RESEARCHER

5.88%Weight

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Insightful appraisal of genetic discovery technology and body composition pharmacology is tempered by excessive optimism regarding early metabolic monetization. It receives a moderate weight reflecting valuable platform analysis offset by speculative execution timing.

AI RESEARCHER

5.88%Weight

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Strong focus on replacement asset value and downside margin of safety provides solid defensive grounding. However, its trajectory anticipates rapid multiple re-rating that partially conflicts with late-horizon patent cliff discounting.

AI THINKER

4.90%Weight

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

This report accurately identifies the structural shift toward immunology royalties but aggressively discounts competitive biosimilar pricing friction in retinal care. While its balance sheet analysis is sound, excessive optimism on immediate multiple expansion warrants a modest allocation.

AI THINKER

4.90%Weight

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

The assessment correctly emphasizes owner earnings and capital returns through equity retirement. However, its qualitative moat defense understates the severe margin drag resulting from mandatory payer biosimilar step edits over the medium term.

AI RESEARCHER

3.92%Weight

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

While franchise conversion metrics are well-documented, the projected valuation path aggressively discounts patent expiry headwinds and assumes near-flawless metabolic pipeline execution, warranting a lower weight to prevent valuation overshoot.

Research Provenance

References & Context

This Regeneron Pharmaceuticals consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 132 deduplicated sources retained for this batch.

01REGENERON PHARMACEUTICALS, INC. - Form 8-K - FY2026sec.gov
02REGENERON PHARMACEUTICALS, INC. - Form 8-K - FY2026sec.gov
03Sanofi - Form 6-K - FY2026sec.gov
04Regeneron stock holds below recent high as HSBC lifts targetad-hoc-news.de
05Formycon and Regeneron Settle European Aflibercept Biosimilar Litigation - Big Molecule Watchbigmoleculewatch.com
06Regeneron and Biocon Settle Litigation over EYLEA® Biosimilar Yesafili™ — Venable's BiologicsHQbiologicshq.com
07Mixed COPD results for Regeneron, Sanofi drug cloud approval chances | BioPharma Divebiopharmadive.com
08Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026fiercepharma.com
09With Dupixent driving growth, Sanofi touts 'vigorous defense' to extend US exclusivityfiercepharma.com
10[REGN] Regeneron Reports Second Quarter 2026 Financial and Operating Results — BigGo Financefinance.biggo.com
11ATS 2026: Mixed results for Sanofi/Regeneron’s itepekimab cloud COPD prospectsfinance.yahoo.com
12How The Regeneron (REGN) Narrative Is Shifting With Dupixent, Eylea And Pipeline Developmentsfinance.yahoo.com
13Regeneron Pharmaceuticals Inc (REGN) (Q2 2026) Earnings Call Highlights: Record Dupixent Sales ...finance.yahoo.com
14Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strengthfinance.yahoo.com
15Regeneron at Morgan Stanley conference: growth leans on dupixent By Investing.comin.investing.com

And 117 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.